Jpmorgan Chase & CO Cassava Sciences Inc Put Options Transaction History
Jpmorgan Chase & CO
- $1.27 Trillion
- Q1 2025
Put Options
0 transactions
| Quarter | Operation | Price Per put | puts change | puts Held | SEC Form |
|---|---|---|---|---|---|
| Quarter | Operation | Price Per put | puts change | puts Held | SEC Form |
Others Institutions Holding SAVA
# of Institutions
155Shares Held
15.7MCall Options Held
1.67MPut Options Held
1.26M-
Black Rock Inc. New York, NY3.22MShares$6.86 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.44MShares$5.2 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA1.03MShares$2.19 Million0.0% of portfolio
-
David A. Siegel Two Sigma Advisers, LP | New York, Ny909KShares$1.94 Million0.0% of portfolio
-
State Street Corp Boston, MA874KShares$1.86 Million0.0% of portfolio
About CASSAVA SCIENCES INC
- Ticker SAVA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 40,097,900
- Market Cap $85.4M
- Description
- Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2b clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's...